Impact of the Leu7Pro polymorphism of preproNPY on diurnal NPY and hormone secretion in type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 5, 2007, Pages 281-286

  Jaakkola, U ^a,b   Koulu, M ^a   Karvonen, M K ^c,d   Seppala H ^b   Pesonen, U ^a   Vahlberg, T ^a   Kallio, J ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU CITY HOSPITAL   (Finland)

^c Hormos Medical Ltd   (Finland)

^d Health Center of Turku   (Finland)

Author keywords

Diabetes; Hormone secretion; NPY polymorphism

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROCORTISONE; INSULIN; LEPTIN; LEUCINE; METFORMIN; NEUROPEPTIDE Y; PROLACTIN; PROLINE; REPAGLINIDE; SULFONYLUREA;

ADRENERGIC STIMULATION; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CARDIOVASCULAR FUNCTION; CAUCASIAN; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HEART RATE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; RISK FACTOR; VASCULAR DISEASE;

AGED; AMINO ACID SUBSTITUTION; BLOOD GLUCOSE; BLOOD PRESSURE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROCORTISONE; LEPTIN; LEUCINE; MALE; MIDDLE AGED; NEUROPEPTIDE Y; POLYMORPHISM, GENETIC; PROLINE; PROTEIN PRECURSORS;

EID: 34249934436     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-977696     Document Type: Article

References (32)

1. Arreola F, Paniagua R, Herrera J, Diaz-Bensussen S, Mondragon L, Bermudez JA, Perez Pasten E, Villalpando S. Low plasma zinc and androgen in insulin-dependent diabetes mellitus. Arch Androl 1986; 16: 151-154
2. Bernardi L, Ricordi L, Lazzari P, Solda P, Calciati A, Ferrari MR, Vandea I, Finardi G, Fratino P. Impaired circadian modulation of sympathovagal activity in diabetes. A possible explanation for altered temporal onset of cardiovascular disease. Circulation 1992; 86: 1443-1452
3. Bischoff A, Michel MC. Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtype. Endocrinology 1998a; 139: 3018-3021
4. Bischoff A, Michel MC. Renal effects of neuropeptide Y. Pflugers Arch 1998b; 435: 443-453
5. Brelje TC, Scharp DW, Lacy PE, Ogren L, Talamantes F, Robertson M, Friesen HG, Sorenson RL. Effect of homologous placental lactogens, prolactins, and growth hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets: implication for placental lactogen regulation of islet function during pregnancy. Endocrinology 1993; 132: 879-887
6. Castan I, Valet P, Quideau N, Voisin T, Ambid L, Laburthe M, Lafontan M, Carpene C. Antilipolytic effects of alpha 2-adrenergic agonists, neuropeptide Y, adenosine, and PGE1 in mammal adipocytes. Am J Physiol 1994; 266: R1141-1147
7. Ding B, Kull B, Liu Z, Mottagui-Tabar S, Thonberg H, Gu HF, Brookes AJ, Grundemar L, Karlsson C, Hamsten A, Arner P, Ostenson CG, Efendic S, Monne M, von Heijne G, Eriksson P, Wahlestedt C. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul Pept 2005; 127: 45-53
8. Ding B. Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm 2003; 110: 1199-1204
9. Djursing H, Nyholm HC, Hagen C, Molsted-Pedersen L. Depressed prolactin levels in diabetic women with anovulation. Acta Obstet Gynecol Scand 1982; 61: 403-406
10. Holstad M, Sandler S. Prolactin protects against diabetes induced by multiple low doses of streptozotocin in mice. J Endocrinol 1999; 163: 229-234
11. Jaakkola U, Kuusela T, Jartti T, Pesonen U, Koulu M, Vahlberg T, Kallio J. The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression and increased cardiovascular responsiveness to norepinephrine during oral glucose-tolerance test. J Clin Endocrinol Metab 2005; 90: 3646-3652
12. Jansson PA, Eliasson B, Lindmark S, Eriksson JW. Endocrine abnormalities in healthy first-degree relatives of type 2 diabetes patients-potential role of steroid hormones and leptin in the development of insulin resistance. Eur J Clin Invest 2002; 32: 172-178
13. Kallio J, Pesonen U, Jaakkola U, Karvonen MK, Helenius H, Koulu M. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. J Clin Endocrinol Metab 2003; 88: 3278-3283
14. Kallio J, Pesonen U, Kaipio K, Karvonen MK, Jaakkola U, Heinonen OJ, Uusitupa MI, Koulu M. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J 2001a; 15:1242-1244
15. Kallio J, Pesonen U, Karvonen MK, Kojima M, Hosoda H, Kangawa K, Koulu M. Enhanced exercise-induced GH secretion in subjects with Pro7 substitution in the prepro-NPY. J Clin Endocrinol Metab 2001b; 86: 5348-5352
16. Karvonen MK, Valkonen VP, Lakka TA, Salonen R, Koulu M, Pesonen U, Tuomainen TP, Kauhanen J, Nyyssonen K, Lakka HM, Uusitupa MI, Salonen JT. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001; 159: 145-151
17. Karvonen MK, Koulu M, Pesonen U, Uusitupa MI, Tammi A, Viikari J, Simell O, Ronnemaa T. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with birth weight and serum triglyceride concentration in preschool aged children. J Clin Endocrinol Metab 2000; 85: 1455-1460
18. Karvonen MK, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker JM, Hart LM, Valve R, Uusitupa MI. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 1998; 4: 1434-1437
19. Koulu M, Movafagh S, Tuohimaa J, Jaakkola U, Kallio J, Pesonen U, Geng Y, Karvonen MK, Vainio-Jylha E, Pollonen M, Kaipio-Salmi K, Seppala H, Lee EW, Biggins RD, Zukowska Z. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann Med 2004; 36: 232-240
20. Li S, Hong M, Fournier A, St-Pierre S, Pelletier G. Role of neuropeptide Y in the regulation of gonadotropin-releasing hormone gene expression in the rat preoptic area. Brain Res Mol Brain Res 1994; 26: 69-73
21. McCulloch CE, Searle SR. Generalized, Linear, and Mixed Models. John Wiley & Sons, New York, 2001
22. Morgan DG, Kulkarni RN, Hurley JD, Wang ZL, Wang RM, Ghatei MA, Karlsen AE, Bloom SR, Smith DM. Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells. Diabetologia 1998; 41: 1482-1491
23. Nilsson T, Lind H, Brunkvall J, Edvinsson L. Vasodilation in human subcutaneous arteries induced by neuropeptide Y is mediated by neuropeptide Y Y1 receptors and is nitric oxide dependent. Can J Physiol Pharmacol 2000; 78: 251-255
24. Niskanen L, Karvonen MK, Valve R, Koulu M, Pesonen U, Mercuri M, Rauramaa R, Toyry J, Laakso M, Uusitupa MI. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab 2000a; 85: 2266-2269
25. Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen MK, Valve R, Pesonen U, Laakso M, Uusitupa MI, Koulu M. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 2000b; 108: 235-236
26. Nordman S, Ding B, Ostenson CG, Karvestedt L, Brismar K, Efendic S, Gu HF. Leu7Pro Polymorphism in the Neuropeptide Y (NPY) Gene is Associated with Impaired Glucose Tolerance and Type 2 Diabetes in Swedish Men. Exp Clin Endocrinol Diabetes 2005; 113: 282-287
27. Pettersson-Fernholm K, Karvonen MK, Kallio J, Forsblom CM, Koulu M, Pesonen U, Fagerudd JA, Groop PH. FinnDiane Study Group. Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients. Diabetes Care 2004; 27: 503-509
28. Straub RH, Herfarth H, Falk W, Andus T, Scholmerich J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J Neuroimmunol 2002; 126: 116-125
29. Uckaya G, Ozata M, Bayraktar Z, Erten V, Bingol N, Ozdemir IC. Is leptin associated with diabetic retinopathy? Diabetes Care 2000; 23: 371-376
30. Wallerstedt SM, Skrtic S, Eriksson AL, Ohlsson C, Hedner T. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J Hypertens 2004; 22: 1277-1281
31. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, Grant DS. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998; 83: 187-195
32. Zukowska-Grojec Z, Neuropeptide Y. A novel sympathetic stress hormone and more. Ann N Y Acad Sci 1995; 771: 219-233